<DOC>
	<DOCNO>NCT00209352</DOCNO>
	<brief_summary>The objective study prevent reactivation herpes zoster first year transplant .</brief_summary>
	<brief_title>Long-Term Oral Acyclovir Usage Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant</brief_title>
	<detailed_description>Herpes zoster infection occur 30 % allogeneic hematopoietic cell transplant ( HCT ) recipients history varicella zoster virus ( VZV ) infection . A safe effective prevention strategy establish . 77 marrow allograft recipient risk VZV reactivation randomize oral acyclovir 800 mg twice daily placebo give day 30 day 365 follow toxicity clinical evidence herpes zoster infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>10 year old Both sex ( male female ) Allogeneic transplant patient hematologic malignancy aplastic anemia Previous intolerance acyclovir Patients unavailable followup Patients drug compliance may problem Evidence active VZV infection VZV infection initial 1 month transplant Pregnant woman , lactate woman , use adequate contraception Creatinine &gt; 3.0 mg/dl .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Varicella Zoster Virus Infection</keyword>
	<keyword>VZV infection</keyword>
	<keyword>Oral Acyclovir</keyword>
	<keyword>Allogeneic Bone Marrow Transplantation</keyword>
	<keyword>Allogeneic Hematopoietic Cell Transplantation</keyword>
</DOC>